American Journal of Physiology Biochemistry and Pharmacology, 2023
VOL 13, NO. 08, PAGE 01-02

OPINION ARTICLE

Open Access

Orphan Drug Development: Challenges and Opportunities in Rare Disease Treatment

Okella Gonzo*

Department of Medicine, Kyambogo University, Kampala, Uganda

ARTICLE HISTORY
Received: 28-Jul-2023, Manuscript No: AJPBP-23-115609;
Editor assigned: 31-Jul-2023, PreQC No. AJPBP-23-115609 (PQ);
Reviewed: 14-Aug-2023, QC No. AJPBP-23-115609;
Revised: 21-Aug-2023, Manuscript No. AJPBP-23-115609 (R);
Published: 28-Aug-2023

Description

In the extensive pharmaceutical industry, there exists a category of drugs known as "orphan drugs" that serve a unique and vital purpose. Orphan drugs are designed to treat rare diseases, those afflictions that affect a small fraction of the population. While these diseases may individually impact only a few, collectively, they constitute a significant public health challenge. This article discusses about the significance of orphan drugs, their development, challenges, and the hope they offer to patients facing rare diseases.

Orphan diseases, also referred to as rare diseases, are conditions that affect a relatively small number of individuals. In the United States, a disease is classified as rare if it affects fewer than 200,000 people at any given time. Despite their rarity, there are over 7,000 known rare diseases, collectively affecting millions of people worldwide. Many of these diseases are genetic and can manifest in various ways, often causing debilitating symptoms and shortened lifespans.[1,2]

The challenge of rare diseases

The scarcity of individuals affected by each rare disease poses unique challenges. Because they are so infrequent, these conditions often receive little attention from pharmaceutical companies, making it financially unattractive to develop drugs for them. The lack of treatment options compounds the suffering of patients and their families, leaving them feeling neglected by the healthcare system.[3]

The development of orphan drugs

The development of orphan drugs is a complex and lengthy process. It commonly starts with identification of a rare disease and understanding its genetic or molecular basis. Researchers then work to discover potential drug targets and develop compounds that can address the underlying causes or alleviate the symptoms of the disease.

One of the main incentives for pharmaceutical companies to invest in orphan drug development is the Orphan Drug Act in the United States, passed in 1983. This legislation provides various incentives, including tax credits, grants, and extended market exclusivity, to encourage companies to pursue orphan drug development. Similar orphan drug regulations exist in many other countries, further stimulating research and development efforts.[4,5]

Challenges in orphan drug development

Despite the incentives and the noble goal of alleviating suffering among those with rare diseases, orphan drug development is not without its challenges:

Small patient populations: The small number of patients with rare diseases makes conducting clinical trials difficult. Recruiting enough participants for a meaningful study can be challenging, and traditional statistical methodologies may not apply.

High costs: Developing an orphan drug can be expensive. The limited market size means that potential revenues are lower compared to drugs targeting more common conditions. This financial risk can deter pharmaceutical companies.

Regulatory hurdles: Regulatory agencies must balance the need for safety and efficacy with the urgency to provide treatment options for rare disease patients. Navigating these regulatory pathways can be complex.

Disease complexity: Rare diseases are often poorly understood, and their genetic or molecular basis

Contact: Okella Gonzo, Email id: Okellagonzo56@gmail.com

can be complex. This complexity can slow down the drug development process.

The impact of orphan drugs

Despite these challenges, orphan drugs have had a profound impact on the lives of those affected by rare diseases. They encourage where there was once despair, providing treatments that can improve quality of life, slow disease progression, or even cure some conditions.

Moreover, the development of orphan drugs often leads to advances in our understanding of the underlying biology of rare diseases. The knowledge gained from studying these conditions can have broader implications for the field of medicine, potentially shedding light on more common diseases as well.[6,7]

Orphan drugs represent a possibility for individuals and families facing the challenges of rare diseases. They are evidence to the power of scientific research and innovation to make a difference in the lives of those who need it most. While the development of orphan drugs comes with its share of obstacles, the impact they have on patients and the medical community is immeasurable.[8]

References

[1] Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today 2012;17(13-14):660-664.

[2] Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. Jama 2011;305(22):2320-2326.

[3] Gerke S, Pattinson SD. EU marketing authorisation of orphan medicinal products and its impact on related research. Eur J Health Law 2017;24(5):541-564.

[4] Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis 2011;6(1):1-10.

[5] Giannuzzi V, Conte R, Landi A, Ottomano SA, Bonifazi D, Baiardi P, et al. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet J Rare Dis 2017;12(1):1-1.

[6] Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy 2010;8:343-350.

[7] Arno PS, Bonuck K, Davis M. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act. Milbank Q 1995;231-52.

[8] Gibson S, Raziee HR, Lemmens T. Why the shift? taking a closer look at the growing interest in niche markets and personalized medicine. World Med Health Policy 2015;7(1):3-27.